Implementation of the Intravitreal Injection Service Administered by Nurses: Safety and Satisfaction of the Patients Served
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Macular Edema
- Sponsor
- Corporacion Parc Tauli
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Complications presented during the IIV technique
- Status
- Enrolling By Invitation
- Last Updated
- last year
Overview
Brief Summary
Introduction:
Intravitreal injections involve medication administration into the eye to treat ocular diseases and protect vision. Through an injection, the medication is introduced into the vitreous cavity, an area located at the back of the eye, behind the lens. The intravitreal injection (IVI) is a minimally invasive process administered at personalized regular intervals. It is a common procedure in ophthalmology for patients who require it. International experiences demonstrate that administering intravitreal injections, especially by nurses trained in aseptic techniques, is feasible without compromising patient safety. The project presented is based on a new care model rooted in interdisciplinary collaboration in the IVI process, operationalizing it as a functional unit. This is a great opportunity to expand the scope of practice for nurses and to demonstrate, as has been done in other countries, that the same procedure currently performed by ophthalmologists can be carried out with equal safety.
Objective:
To evaluate the safety of implementing a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology at Corporation Parc Tauli.
Method:
Observational evaluation study of a care process within the functional Ophthalmology Unit, consisting of protocol application for intravitreal injection by trained nurses. Data will be collected from users receiving care from the intravitreal injection service administered by nurses under a consensual procedure within the unit. Users meeting the inclusion criteria will be eligible. Nurses will be trained internally at CCSPT by the ophthalmology team. User participation will be voluntary. Informed consent will be obtained. Data collection during the process of care will include recording selected variables. Data collection will be carried out between 2024 and 2025. The study will be conducted over 3 years.
Application and Impact:
The development of this project will allow for a safe, more efficient redistribution of our resources. The functional unit is based on a group of professionals who work and make decisions jointly. The new distribution will enable ophthalmologists to expand their availability for more complex procedures. In the future, it is expected to increase the number of users who can benefit from the IVI service and to initiate advanced competencies in the role of the ophthalmology nurse.
Investigators
Susana Santos-Ruiz
Nurse, Phd Health of Science
Corporacion Parc Tauli
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Complications presented during the IIV technique
Time Frame: In each injection during and after the procedure until the end of treatment
Complications presented during IIV 1.1 Pain from the placement of the blepharostat: It will be recorded as: 0=No ; 1=Yes 1.2 Pain during the injection: It will be recorded as: 0=No ; 1=Yes 1.3 Subconjunctival haemorrhage. It will be recorded as: 0=No ; 1=Yes 1.4 Post-injection ocular hypertension: It will be recorded as: 0=No ; 1=Yes 1.5 Other Complications (specified with free text)
Late post-procedure complications
Time Frame: In each injection during and after the procedure until the end of treatment
Complications that arise when users leave the service. In this case, users will be asked in subsequent visits about the complications presented. They can also be reviewed from the patient's medical history. 2.1. Pain: If pain appeared in the first 48h. It will be recorded using a Likert scale from 0 to 10, where 0 is no pain and 10 maximum pain. 2.2 Subconjunctival haemorrhage: It will be recorded as: 0=No ; 1=Yes 2.3. Ocular hypertension: It will be recorded as: 0=No ; 1=Yes 2.4. Visual ability to perform AVDs: To assess the current state of their vision, we will be asked if they currently notice that they can do their usual activities better or not. It will be recorded as: 0= Worsening ; 1= Maintenance; 2= Improvement 2.5. Visit to the emergency room (or ophthalmology service) for problems after the IIV. It will be recorded as: 0=No ; 1=Yes, and free text that answer to what problem did they present.
Secondary Outcomes
- Ocular comorbidity(At the beginning of treatment)
- Anxiety level(In each injection until the end of the treatment)
- Ophthalmologist visit during the session(In each injection until the end of the treatment)
- Companion(In each injection until the end of the treatment)
- Sociodemographic variables(At the beginning of treatment)
- Ocular Diagnosis(At the beginning of treatment)
- Visit to the ophthalmologist between therapies(In each injection until the end of the treatment)
- Treated eye(In each injection until the end of the treatment)
- Date of treatment indication(At the beginning of treatment)
- Previous experience(At the beginning of treatment)
- Patient Pain(In each injection until the end of the treatment)
- IVI Medication(In each injection until the end of the treatment)
- Patient Satisfaction(In each injection until the end of the treatment)